surmount-1 tirzepatide weight loss nondiabetic SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, Tirzepatide for Obesity Treatment and

With generic semaglutide just approved in Canada first in the G7 and prices expected to drop to a third of current cost, the number of patients asking it is about to multiply significantly

Just as importantly, the symptoms patients attribute to "low GH" fatigue, poor recovery, low energy overlap heavily with hypothyroidism, depression, sleep apnea, and low testosterone, so those causes should be ruled out first

"I was starting to feel like I was just this negative burden for everybody," she says

On November 8, 2023 , the FDA approved medications containing tirzepatide under the brand names Mounjaro and Zepbound for type 2 diabetes and weight management in qualifying adults